Abstract:The current 'fixed-dosage strategy' approach to medicine, means there is much inter-individual variation in drug response. Pharmacogenetics is the study of how inter-individual variations in the DNA sequence of specific genes affect drug responses. This article will highlight current pharmacogenetic knowledge on important drug metabolizing enzymes, drug transporters and drug targets to understand interindividual variability in drug clearance and responses in clinical practice and potential use in personalized medicine. Polymorphisms in the cytochrome P450 (CYP) family may have had the most impact on the fate of pharmaceutical drugs. CYP2D6, CYP2C19 and CYP2C9 gene polymorphisms and gene duplications account for the most frequent variations in phase I metabolism of drugs since nearly 80% of drugs in use today are metabolised by these enzymes. Approximately 5% of Europeans and 1% of Asians lack CYP2D6 activity, and these individuals are known as poor metabolizers. CYP2C9 is another clinically significant drug metabolising enzyme that demonstrates genetic variants. Studies into CYP2C9 polymorphism have highlighted the importance of the CYP2C9*2 and CYP2C9*3 alleles. Extensive polymorphism also occurs in a majority of Phase II drug metabolizing enzymes. One of the most important polymorphisms is thiopurine S-methyl transferases (TPMT) that catalyzes the S-methylation of thiopurine drugs. With respect to drug transport polymorphism, the most extensively studied drug transporter is P-glycoprotein (P-gp/MDR1), but the current data on the clinical impact is limited. Polymorphisms in drug transporters may change drug's distribution, excretion and response. Recent advances in molecular research have revealed many of the genes that encode drug targets demonstrate genetic polymorphism. These variations, in many cases, have altered the targets sensitivity to the specific drug molecule and thus have a profound effect on drug efficacy and toxicity. For example, the beta (2)-adrenoreceptor, which is encoded by the ADRB2 gene, illustrates a clinically significant genetic variation in drug targets. The variable number tandem repeat polymorphisms in serotonin transporter (SERT/SLC6A4) gene are associated with response to antidepressants. The distribution of the common variant alleles of genes that encode drug metabolizing enzymes, drug transporters and drug targets has been found to vary among different populations. The promise of pharmacogenetics lies in its potential to identify the right drug at the right dose for the right individual. Drugs with a narrow therapeutic index are thought to benefit more from pharmacogenetic studies. For example, warfarin serves as a good practical example of how pharmacogenetics can be utilized prior to commencement of therapy in order to achieve maximum efficacy and minimum toxicity. As such, pharmacogenetics has the potential to achieve optimal quality use of medicines, and to improve the efficacy and safety of both prospective and licensed drugs.

Genetic polymorphism of CYP2D6 and its influence on the personalized usage of antipsychotics

Identification and Functional Assessment of EightCYP3A4Allelic Variants39–46Detected in the Chinese Han Population

Awareness of Genetic Polymorphism in Drug Metabolizing Enzymes and Transporters May Promote Personalized Type 2 Diabetes Management [Letter]

Progress in research of cytochrome P450 3A4 gene polymorphism

The Cytochrome P450 2D6 (CYP2D6) Enzyme Polymorphism: Screening Costs and Influence on Clinical Outcomes in Psychiatry

Clinical Pharmacogenetics and Potential Application in Personalized Medicine.

Influence of CYP2D6 Gene Polymorphisms on the Pharmacokinetics of Aripiprazole in Healthy Chinese Subjects.

Progress on the relationship between genetic polymorphism of CYP2D6 and endocrine therapy of breast cancer

GENETIC BIAS COULD NOT BE IGNORED IN CLINICAL TRIALS

Effect of Cyp2d6 Genetic Polymorphism on the Metabolism of Citalopram in Vitro

Advance in Genetic Polymorphism of Cytochrome P450 2C19

Identification and in vitro functional assessment of 10 CYP2C9 variants found in Chinese Han subjects

CYP2D6 pharmacogenetics and phenoconversion in personalized medicine

Clinical applications of CYP genotyping in psychiatry

A Systematically Combined Genotype And Functional Combination Analysis Of Cyp2e1, Cyp2d6, Cyp2c9, Cyp2c19 In Different Geographic Areas Of Mainland China - A Basis For Personalized Therapy

Influence of CYP2D6 Genotypes on the Pharmacokinetics and Treatment Effect of Risperidone in Patients Using Extended-Release Risperidone Microspheres for Intramuscular Injection

Polymorphisms of Drug-Metabolizing Enzyme CYP2E1 in Chinese Uygur Population

Progress in relationship of cytochrome P450 1A2 genetic polymorphism,substance metabolism and carcinogenesis

Insights into CYP2B6-mediated drug-drug interactions

Effect of CYP2D6 polymorphisms on plasma concentration and therapeutic effect of risperidone

Advances in Human Cytochrome P450 and Personalized Medicine